Cadila attacks Teva over risperidone patent; Ex-GSK chair Sykes takes new post;

> India's Zydus Cadila has sued Teva Pharmaceutical industries in the U.S., seeking damages for alleged antitrust violations and unfair trade practices related to risperidone, the generic version of Johnson & Johnson's antipsychotic drug Risperdal. Report

> UK medical technology company BioCeramic Therapeutics announced that Sir Richard Sykes, former chairman of GlaxoSmithKline, has accepted the role of Chairman of its Board of Directors. Release

> Kansas Attorney General Steve Six sued 13 drugmakers Friday, alleging they unlawfully inflated drug costs paid by taxpayers through the state’s Medicaid program. Report

> Teva Pharmaceutical Industries said Monday it will receive a $100 million cash settlement from an institution acting as a broker for the drug developer's auction-rate securities. Teva release

> Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers. Report

> One of the nation’s largest clinical laboratory companies has halted sales of a controversial blood test aimed at early detection of ovarian cancer after receiving a warning from the FDA. Report

> The Bill & Melinda Gates Foundation--the world's largest private philanthropy-- is handing out $100 million to fund to 104 research projects that explore novel ways to solve some of the world's most pressing medical problems. Report

> In a release, India's Glenmark Pharmaceuticals said its partner Eli Lilly has suspended further clinical development for GRC 6211 for osteoarthritis pain. The companies didn't give an explanation for the move, saying only that Glenmark and Lilly are currently in discussions on the way forward. Report

> Finland's BioTie Therapies has agreed to purchase German's Elbion, forming a company that will focus on CNS disorders and inflammatory diseases. Report

> In a study published in The Lancet, Europe's NeuroSearch announced strong Phase II for tesofensine, the company's anti-obesity compound. The hunger-suppressing drug produced a weight loss twice that of currently approved obesity drugs Reductil/Meridia and Acomplia. Report

And Finally... Expect to see more articles like this one about the legal doctrine of preemption, as the U.S. Supreme Court prepares to hear arguments on a related case next week. Report